ISELIN, N.J., Oct. 30 /PRNewswire-FirstCall/ -- SyntheMed, Inc. , a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products, announced today that Robert P. Hickey, President and CEO, will present at the 8th Annual Rodman & Renshaw Healthcare Conference on Wednesday, November 8, 2006 at 12:05 p.m., EST, at the New York Palace Hotel in New York City. Mr. Hickey will present a company overview.
The presentation will be available via web cast for 90 days, beginning on November 8, 2006, and can be viewed by clicking on the following link: http://www.wsw.com/webcast/rrshq10/symd/
About SyntheMed, Inc.
SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology. The company’s lead product, REPEL-CV(R), a bioresorbable adhesion barrier intended for use in cardiac surgery received CE Mark approval in the European Union in August 2006. REPEL-CV has been launched in the EU and certain Southeast Asian markets through a network of independent distributors. In September 2006, the company released positive efficacy data from the REPEL-CV multi-center pivotal clinical trial. The company intends to submit a Premarket Approval (PMA) application to the FDA that, if approved, would allow for REPEL-CV to be marketed in the U.S. SyntheMed plans to launch the product in the U.S. in mid 2007 through a direct sales force. The worldwide market for cardiac anti-adhesion products is estimated to be in excess of $300 million annually.
Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company’s efforts to obtain and maintain required FDA and other regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company’s future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2005 and Registration Statement on SB-2 declared effective on August 1, 2006 (No. 333- 134746) for a description of these, as well as other, risks and uncertainties.
Media Contact: Investor Contact: Francesca T. DeVellis Tara Spiess Senior Vice President TS Communications Group, LLC Feinstein Kean Healthcare 914-921-5900 617-577-8110 Spiess@biotechirpr.comFrancesca.devellis@fkhealth.com
SyntheMed, Inc.
CONTACT: Media Contact: Francesca T. DeVellis, Senior Vice President ofFeinstein Kean Healthcare, +1-617-577-8110,Francesca.devellis@fkhealth.com; or Investor Contact: Tara Spiess of TSCommunications Group, LLC, +1-914-921-5900, Spiess@biotechirpr.com, bothfor SyntheMed, Inc.
